CD46 Expression is an Unfavorable Prognostic Factor in Breast Cancer Cases
CD46 Expression is an Unfavorable Prognostic Factor in Breast Cancer Cases
复制标题
DOI：
10.1097/pai.0b013e31821a0be9
复制
发表时间：
2011-12-01
影响因子：
1.6
通讯作者：
Surowiak, Pawel
中科院分区：
文献类型：
--
作者：
Maciejczyk, Adam;Szelachowska, Jolanta;Surowiak, Pawel
膜辅因子蛋白 CD46 代表补体抑制剂，可保护自体细胞免受补体介导的细胞毒性。对于肿瘤细胞，CD46 可能表现出保护它们免受宿主免疫反应的潜力。本研究旨在评估乳腺癌中 CD46 表达的预后意义。对 70 个乳腺癌样本进行了分析。使用针对 CD46 的单克隆抗体对所研究肿瘤的石蜡切片进行免疫组织化学反应。对免疫组织化学反应和临床观察的结果进行统计分析。多变量分析显示CD46的表达和淋巴结受累代表无病生存和总生存的独立危险因素。 Kaplan-Meier 分析显示，与 CD46 阳性肿瘤患者相比，CD46 阴性肿瘤患者的无进展时间和总生存时间更长。该研究表明乳腺癌表现出 CD46 表达，并且与较差的预后相关。
The membrane cofactor protein, CD46 represents a complement inhibitor, which protects autologous cells from complement-mediated cytotoxicity. On tumor cells, CD46 may exhibit the potential to protect them from immune responses of the host. The present study aimed at evaluation of prognostic significance of CD46 expression in breast cancers. The analyses were performed on 70 samples of breast cancer. Immunohistochemical reactions were performed on paraffin sections of studied tumors using monoclonal antibodies directed against CD46. Results of the immunohistochemical reactions and of clinical observations were subjected to statistical analysis. Multivariate analysis showed that expression of CD46 and involvement of lymph nodes represent independent risk factors for disease-free survival and overall survival. Kaplan-Meier analysis showed that patients with tumors negative for CD46 have an increased progression-free time and overall survival time as compared with patients with the CD46-positive tumors. The study demonstrates that breast cancers manifest CD46 expression and that it is linked to a less favorable prognosis.